Silexion Therapeutics reported positive preclinical data for SIL204 showing increased MHC-I expression in KRAS-mutated pancreatic cancer cells, supporting potential combination with checkpoint inhibitors.
Key takeaways
SIL204 significantly increased MHC-I expression in KRAS G12R pancreatic cancer cells, potentially restoring immune visibility.
The finding suggests SIL204 may enhance responsiveness to anti-PD-1 therapies like pembrolizumab.
Pancreatic cancer is immunologically resistant; MHC-I upregulation could address immune evasion.
Data supports SIL204's dual mechanism: direct anti-tumor activity and immune modulation.
Preclinical results are preliminary; further studies are needed to confirm clinical utility.